Clinical trials: Tace
Recurrent Hepatocellular Carcinoma, Lenvatinib
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage.
- Conditions
- Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy, Ablation
- Trial name
- NCT06609850
- Testing
- TACE, Ablation, Lenvatinb
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
This retrospective multicenter study aims to evaluate whether radiographic microvascular invasion (MVI) status can predict treatment response in patients with intermediate-stage hepatocellular carcinoma (HCC) receiving…
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI), Tyrosine Kinase Inhibitors
- Trial name
- NCT07449065
- Testing
- TKI, TACE
- Where
- China
- Volunteers
- 324 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC
It is postulated that all arterial tumor feeders supplying a HCC tumor are interconnected with each other through the tumor sinusoid, such that when one of the feeders is catheterized for delivery of a liquid embolic agent, the…
- Trial name
- NCT04641637
- Testing
- TACE
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Hepatocellular Carcinoma
A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC
This clinical trial is a prospective, randomized, controlled and multicenter study.And the trial is going to better control intrahepatic tumors for hepatocellular carcinoma(HCC) patients who meet the inclusion criterion.The…
- Trial name
- TACE-EBRT (NCT03116984)
- Testing
- Transcatheter arterial chemoembolization, External- beam radiotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC
TACE is considered the standard treatment for unresectable HCC on the basis of the fact that there are no alternative to curative procedures.But the optimal combined regimen is still unclear.
- Trial name
- NCT01229839
- Testing
- Embolization, Infusion of anticancer agent, Infusion of mixture of anticancer agent and lipiodol
- Where
- China
- Volunteers
- 668 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC). It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor associated antigens, potentially increasing…
- Trial name
- NCT05776875
- Testing
- Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Carcinoma, Hepatocellular
3T MRI to Predict TACE Response of HCC
This study is a prospective clinical study using DCE-MRI, DWI and MRS in 3T scanner to evaluate tumors in patients with unresectable HCC after TACE. A total of 100 subjects will be recruited.
- Trial name
- NCT02070822
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC)
The presence of portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC) is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months.
- Trial name
- NCT02290977
- Testing
- Scheduled interval TACE - RT
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
The purpose of the study is to observe the effect of TACE/HAIC combined with lenvatinib and sintilimab as a neoadjuvant therapy before liver resection in preventing the recurrence in high-risk patients with hepatocellular…
- Trial name
- NCT05250843
- Testing
- TACE/HAIC, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the hypoxia caused by TACE in surviving tumor cell leads to release of angiogenic and growth factors contributing to…
- Conditions
- PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms, Carcinoma, Hepatocellular, Digestive System Neoplasms
- Trial name
- NCT01556815
- Testing
- Transarterial Chemoembolization (TACE), Sorafenib in combination with TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
The purpose of this study is to develop better ways to treat liver cancer, known as hepatocellular carcinoma or HCC, while it is still in the liver.
- Trial name
- NCT02513199
- Testing
- SBRT, TACE
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Liver Cancer, Pain Postoperative
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
This phase III, randomized, prospective clinical study, aiming to compare the analgesic effects of celecoxib, parecoxib, and oxycodone in patients with inoperable hepatic carcinoma undergoing TACE procedure in postoperative pain…
- Trial name
- NCT03059238
- Testing
- Celecoxib 200mg oral capsule, parecoxib sodium, controlled-release oxycodone
- Where
- China
- Volunteers
- 213 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC
A primary hepatocellular carcinoma (HCC) is generally regarded as unresectable if the future liver remnant (FLR)≤40％ of total liver volume in patient with underlying liver disease, such as hepatitis B.
- Trial name
- TACEPVE (NCT00834158)
- Testing
- TACE, PVE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Although resection provided survival benefit for selected HCC patients with PVTT, the recurrence rate is still high for those patients.
- Trial name
- NCT06031285
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
The aim of this study is to clarify the safety and efficacy of DEB-TACE combined with SALOX-HAIC in the treatment of unresectable advanced primary liver cancer.
- Trial name
- NCT06823050
- Where
- 7 sites in China
- Volunteers
- 59 people
- Sponsor
- Xuhua Duan
Hepatocellular Carcinoma Non-resectable
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed…
- Trial name
- NCT06397235
- Testing
- DEB-TACE+HAIC, DEB-TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Carcinoma, Hepatocellular, Hepatic Carcinoma
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
The IMMUTACE study evaluates the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) nivolumab in combination with transarterial chemoembolization (TACE) in patients with multinodular, intermediate stage…
- Conditions
- Carcinoma, Hepatocellular, Hepatic Carcinoma, Hepatocellular Cancer
- Trial name
- IMMUTACE (NCT03572582)
- Testing
- Nivolumab, TACE
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- AIO-Studien-gGmbH
Hepatocellular Carcinoma (HCC)
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
The goal of this clinical trial is to compare the safety and efficacy of sequential Transarterial Chemoembolization (TACE) and Stereotactic body radiation therapy (SBRT) versus Y90-radioembolisation (SIRT), followed by systemic…
- Trial name
- BIIRTH (NCT07293468)
- Testing
- Transarterial chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), SIRT Yttrium-90
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- Tuen Mun Hospital
Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above.
- Conditions
- Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib, PD-1 Antibody
- Trial name
- NCT04834674
- Testing
- DEB-TACE combined with apatinib and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Hepatocellular Carcinoma
HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large and unresectable hepatocellular…
- Trial name
- NCT03048123
- Testing
- Hepatic arterial infusion, Transarterial chemoembolization, Folfox Protocol
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Sun Yat-sen University